One of the leading South Korean biomedical engineering companies has been selected by the Ministry of Health and Welfare of that country to develop cell maturation technology for pluripotent stem cell-derived cardiomyocytes, by combining and integrating 3D cell bioprinting and microculture environment control technology.
T&R Biofab mainly manufactures bioresorbable scaffolds that aid in the regeneration and reconstruction of tissues and organs using innovative 3D printing technology. The company was founded in 2013 by leveraging 10 years of accumulated research and expertise at Pohang University of Science and Technology (POSTECH) and has seen significant growth in the last few years.
Now it has been selected as a general research institute for a stem cell and regenerative medicine commercialization project that seeks to establish drug response characteristic information of cardiomyocytes derived from starch-potent stem cell lines using resources from the national stem cell bank. As reported by the Korea Biomedical Review […]
Blackstone Resources AG is pleased to announce that it has achieved a series of important milestones for its...